<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966742</url>
  </required_header>
  <id_info>
    <org_study_id>RMC-0485-17</org_study_id>
    <nct_id>NCT03966742</nct_id>
  </id_info>
  <brief_title>Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis</brief_title>
  <official_title>Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study Drug-eluting microbeads (DEB) loaded with Doxorubicin will be delivered into&#xD;
      the target Desmoid Fibromatoses (DF) tissue via selective arterial embolization by&#xD;
      angiographic technique. The objective of the study is to demonstrate the safety and efficacy&#xD;
      of this treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Desmoid Fibromatoses (DF) are locally aggressive lesions associated with substantial&#xD;
      morbidity and potentially mortality, due to invasion of adjacent neurovascular structures and&#xD;
      vital organs. They have no potential for metastasis. Histologically, they are characterised&#xD;
      by mature fibroblasts within a matrix of abundant fibrous stroma. While 5-15% of cases are&#xD;
      seen in patients with Familial Adenomatous Polyposis (FAP) syndrome, the vast majority arise&#xD;
      sporadically.&#xD;
&#xD;
      The etiology of Desmoids remains poorly understood and the therapeutic approaches in their&#xD;
      management remain very diverse. For resectable lesions, surgery is recommended but reported&#xD;
      cure rates range broadly from 12-80%. Systemic treatments range from non-steroidal&#xD;
      anti-inflammatories and anti-estrogenic therapy to targeted tyrosine kinase inhibitors and&#xD;
      cytotoxic chemotherapy, most commonly methotrexate, vinblastine and doxorubicin.&#xD;
&#xD;
      Doxorubicin is an anthracycline with demonstrated efficacy in treating desmoids at systemic&#xD;
      IV doses of 50- 75mg/m2 over 3-4 week cycles. Extended use is limited by dose - dependent&#xD;
      cardiotoxicity which can be seen in up to 36% of patients receiving doses in excess of&#xD;
      550mg/m2. Delayed cardiotoxicity is particularly common and less predictable among pediatric&#xD;
      cancer survivors.&#xD;
&#xD;
      Selective trans-arterial chemo-embolization (TACE) is a method to achieve high tissue drug&#xD;
      concentration with minimal systemic toxicity. Historically, this has been achieved by mixing&#xD;
      doxorubicin with embolic agents such as lipiodol or gelatin sponge in the treatment of&#xD;
      hepatocellular carcinoma (HCC).&#xD;
&#xD;
      Drug-eluting microbeads (DEB) ionically loaded with doxorubicin have shown sustained release&#xD;
      in TACE target tissues with substantially lower serum drug concentrations when compared to&#xD;
      lipiodol TACE.&#xD;
&#xD;
      The present study utilizes DEB's loaded with Doxorubicin delivered into the target DF tissue&#xD;
      via selective arterial embolization by angiographic technique. This study follows a&#xD;
      successful feasibility study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2018</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate of tumor size.</measure>
    <time_frame>At baseline ; 6-10 weeks after each treatment</time_frame>
    <description>Response to treatment. Measured by change in tumor size according to RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1 criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate of tumor biological activity.</measure>
    <time_frame>At baseline ; 6-10 weeks after each treatment</time_frame>
    <description>Response to treatment. Tumor biological activity measured by change in MRI T2 signal intensity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient reported outcomes.</measure>
    <time_frame>At baseline ; 6-10 weeks after each treatment</time_frame>
    <description>Change in clinical symptoms measured by standard clinical patient questionnaires - EORTC QLQ-C30. (Quality of Life Questionnaire).&#xD;
All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high level of functioning, a high score for the global health status / QoL represents a high QoL. Similarly, a high score for a symptom scale represents a high level of symptomatology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event profile (safety)</measure>
    <time_frame>At baseline ; 6-10 weeks</time_frame>
    <description>Treatment safety measured by standard patient questionnaires and clinical evaluation using CTCAE (Common Terminology Criteria for Adverse Events) version 5.0.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetics of Doxorubicin</measure>
    <time_frame>5 minutes, 30 minutes, 1 hour, 12 hours, 24 hours after treatment procedure</time_frame>
    <description>Measurements of blood Doxorubicin concentration (mg/ml) over time, after treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory biomarkers</measure>
    <time_frame>At baseline ; 6-10 weeks</time_frame>
    <description>Immunohistochemistry assay assessing the staining pattern (marked as negative to mildly or strongly positive) for: beta-catenin, keratin, SMA (smooth muscle actin). Ki-67 staining will be scored by percentage.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Desmoid</condition>
  <condition>Desmoid Fibromatosis of Skin</condition>
  <condition>Desmoid Neoplasm of Chest Wall</condition>
  <condition>Desmoid Tumor Caused by Somatic Mutation</condition>
  <condition>Aggressive Fibromatoses</condition>
  <condition>Fibromatosis Desmoid</condition>
  <condition>Desmoid Fibromatosis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorubin-eluting particle embolization for treatment of Desmoid Fibromatosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis</intervention_name>
    <description>Delivery of Doxorubicin selectively into Desmoid Fibromatosis utilizing its vascular supply as a conduit, and ionic loading the doxorubicin onto embolized particles as the drug delivery vehicle.&#xD;
Maximal dose is 75 mg/m2 and at least 50 mg. The bead size is 75-300 MÂµ in a 2 CC syringe.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 3-80 years.&#xD;
&#xD;
          2. Histologically confirmed diagnosis of Desmoids Fibromatosis.&#xD;
&#xD;
          3. After at least one systemic treatment line. Standard first line systemic treatment may&#xD;
             include: Methotrexate, Vinblastine, Doxorubicin, Liposomal Doxorubicin (Doxil), NSAIDS&#xD;
             or hormonal treatment. If first line treatment is renounced, this treatment decision&#xD;
             must be documented. Considering the trend of avoiding surgical treatment, the&#xD;
             documentation must include that the treatment decision is not associated to the&#xD;
             resectability of the tumor.&#xD;
&#xD;
          4. Karnofsky performance status (PS)&gt;50% for patients older than 16 years or Lansky PS&#xD;
             &gt;50% for patients under 16 years.&#xD;
&#xD;
          5. At least one measurable lesion, with a long diameter of at least 30mm, with an&#xD;
             anatomical location accessible for endovascular treatment.&#xD;
&#xD;
          6. T2 signal increase on MRI.&#xD;
&#xD;
          7. No evidence of prior treatment toxicity, adequate washout period after prior&#xD;
             treatment:&#xD;
&#xD;
               -  14 days after myelosuppressive chemotherapy treatment.&#xD;
&#xD;
               -  7 days after GCSF (Granulocyte colony-stimulating factor), 14 days after&#xD;
                  Neulastim.&#xD;
&#xD;
               -  7 days after targeted/biologic treatment.&#xD;
&#xD;
          8. Female patients of childbearing potential must be willing to use an adequate method of&#xD;
             contraception (hormonal, barrier or abstinence) for the treatment period and up to 90&#xD;
             days after the treatment completion.&#xD;
&#xD;
          9. Willing and able to provide written informed consent for the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in another interventional study.&#xD;
&#xD;
          2. Congestive heart failure, characterised by LVEF (Left Ventricular Ejection Fraction) &lt;&#xD;
             50% or Shortening fracture &lt; 27%.&#xD;
&#xD;
          3. Previous treatment with anthracycline of a accumulative dose of more than 360 mg/m2.&#xD;
&#xD;
          4. History of allergic reaction attributed to Doxil or doxorubicin treatment.&#xD;
&#xD;
          5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure (New York Heart Association Class III&#xD;
             or IV), cardiac arrhythmia, or psychiatric illness, social situations that would limit&#xD;
             compliance with study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eldad Elnekave, MD</last_name>
    <phone>+972-3-9377940</phone>
    <email>eldadel@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach-Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eldad Elnekave, MD</last_name>
      <email>eldadel@clalit.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Elnekave E, Atar E, Amar S, Bruckheimer E, Knizhnik M, Yaniv I, Dujovny T, Feinmesser M, Ash S. Doxorubicin-Eluting Intra-Arterial Therapy for Pediatric Extra-Abdominal Desmoid Fibromatoses: A Promising Approach for a Perplexing Disease. J Vasc Interv Radiol. 2018 Oct;29(10):1376-1382. doi: 10.1016/j.jvir.2018.04.009. Epub 2018 Jul 31.</citation>
    <PMID>30075974</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>May 28, 2019</last_update_submitted>
  <last_update_submitted_qc>May 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Eldad Elnekave, MD</investigator_full_name>
    <investigator_title>Director, Clinic Interventional Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
    <mesh_term>Fibroma</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

